Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

NCT04383938 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer
Gastric Cancer
Non Small Cell Lung Cancer
NSCLC
Urothelial Carcinoma
Advanced Solid Tumor

Interventions

DRUG: APR-246 (eprenetapopt) + Pembrolizumab

Sponsor

Aprea Therapeutics